A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

INDIANAPOLIS — Eli Lilly announced Tuesday single-dose vials of weight loss drug Zepbound are now available for patients with a prescription. "I love it. I love the new me," said Mary Beedle, smiling ...

Eli Lilly’s weight loss drug Zepbound generated more than $175 million in just its first few weeks on the market. The company is addressing a market that could reach $100 billion by 2030 ...

Eli Lilly said it has started selling single-dose vials of its uber-popular weight loss drug Zepbound as demand soars – and the smaller doses cost 50% less than all other obesity medicines.

Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 medications have risen in popularity. Investor Alert: Our 10 best stocks ...